Fig. 6From: Primary outcomes of the VIDI study: phase 2, double-masked, randomized, active-controlled study of ASP8232 for diabetic macular edemaMean (SD) VAP-1 activity in plasma (pharmacodynamic analysis set). LDD, last dose dateBack to article page